Results 131 to 140 of about 71,664 (187)

Can Biomarker-Based Monitoring Detect the Early Development of Diastolic Dysfunction During Chemotherapy? [PDF]

Medicina (Kaunas)
Farcaş AD, Goidescu CM, Stoia MA, Anton FP, Pârvu AV, Crişan CHE, Mocan Hognogi DL.   +6 more
europepmc   +1 more source

Metastasis of Invasive Ductal Carcinoma of the Breast to the Uterine Cervix 30 Years Post‐Mastectomy: A Case Report

Journal of Obstetrics and Gynaecology Research, Volume 52, Issue 10, October 2026.
ABSTRACT Metastasis of invasive ductal carcinoma of the breast to the uterine cervix is rare, with only one report of a case occurring more than 20 years after the primary surgery. A 69‐year‐old woman presented with abnormal uterine cervical cytology (atypical glandular cells without tumor diathesis) 30 years after undergoing breast cancer surgery ...
Taro Miyake, Hidenori Sasa, Tsubasa Ito, Takanori Watanabe, Takako Sato, Sho Ogata, Masashi Takano   +6 more
wiley   +1 more source

Reassessing the Role of Anthracyclines in Early HER2-Positive Breast Cancer in the Era of HER2-Targeted Therapy and Treatment De-Escalation: A Systematic Review and Narrative Synthesis. [PDF]

J Clin Med
Myrzabay Z, Askambayeva N, Harahsheh AJ, Ishak R, Aljofan M.   +4 more
europepmc   +1 more source

(S)‐Pyrrolo[1,2‐a]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
Among 30 synthesized pyrrolo[1,2‐a]pyrazine analogs, compounds B1 and B3 showed strong and selective cytotoxicity toward TNBC cells, inducing apoptosis through Akt suppression and JNK activation. Triple‐negative breast cancer (TNBC) remains a major clinical challenge due to the absence of effective targeted therapies.
Narges Hosseininasab, Sou Hyun Kim, Ye‐Mi Kwon, Jungjin Park, Chanhyun Jung, Kwanghee Lee, Beom‐Jun Wi, Su‐Jin Yoo, Soonsil Hyun, Young‐Suk Jung, Jae‐Hwan Kwak   +10 more
wiley   +1 more source

Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study. [PDF]

Ther Adv Med Oncol
Wu F, Lin C, Lin Z, Yang Q, Wu X, Chen B, Li N, Zhang R, Wu X, Huang W, Chen X, Hong Y, Chen K, Liu J.   +13 more
europepmc   +1 more source

Precision Chemistry for Protein Lysine Modification

Chemistry – A European Journal, Volume 32, Issue 34, 11 September 2026.
Selective modification of lysine residues is challenging due to their similar intrinsic reactivity. Inspired by enzymatic recognition, ligand‐guided electrophiles enable site‐selective labeling and functionalization, while ligand‐guided catalyses achieve regioselective installation of bio‐relevant post‐translational modifications.
Mayu Onoda, Motomu Kanai
wiley   +1 more source

Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial. [PDF]

ESMO Open
Huober J, Barrios CH, Niikura N, Jarząb M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Curran M, Eiger D, Lambertini C, Yan I, Krishnan V, Restuccia E, Zhang H.   +14 more
europepmc   +1 more source

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. [PDF]

Target Oncol
Dieras V, Curigliano G, Martin M, Lerebours F, Tsurutani J, Savard MF, Jerzak KJ, Hu X, O'Sullivan CC, Tokunaga E, Okines A, Huang CS, Jacot W, Sohn J, Cronemberger Silva E, Mueller V, Yang S, Granata G, Shen Q, Hamilton E, HER2CLIMB-05 Investigators.   +20 more
europepmc   +1 more source

Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting. [PDF]

J Gastrointest Oncol
Bothara R, Mehta R.
europepmc   +1 more source

⁶⁸Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study. [PDF]

J Nucl Med
Gao S, Zhang Z, Shi C, Cheng C, Ma X, Zhao X, Liu Y.   +6 more
europepmc   +1 more source